Nemolizumab’s latest drug introduction and global launch schedule

Nemolizumab (trade name Nemluvio) is a monoclonal antibody targeting interleukin-31 receptor alpha (IL-31Rα), specifically used to treat chronic itch-related diseases. The drug can significantly relieve itching symptoms and reduce skin inflammation by inhibiting the IL‑31 signaling pathway. It is especially suitable for patients with chronic nodular pruritus and moderate to severe atopic dermatitis. As an innovative biologic, nemolizumab brings a new treatment option to patients with refractory pruritus.

Nemolizumab was first approved for marketing by Chugai Pharmaceuticals in Japan in 2022 under the trade name Mitchga®. It is mainly used for the treatment of nodular pruritus. Subsequently, the drug successively launched clinical trials and registration applications in many regions around the world. In August 20248, the U.S. Food and Drug Administration (FDA< /span>) approved Nemolizumab for the treatment of adult patients with nodular pruritus. In December, the indication was expanded to patients 12 years old and above with moderate to severe atopic dermatitis, marking its important breakthrough in the international market.

The European Medicines Agency (EMA) also gave a positive opinion on the marketing application of nemolizumab at the end of 2024. Subsequently, many European countries successively approved the drug for marketing. In addition, countries and regions such as Canada, Australia, and Singapore are also actively promoting relevant approval processes. Nemolizumab is rapidly expanding its global market territory and bringing good news to more patients with itch-related diseases.

Clinical data shows that nemolizumab can not only quickly relieve itching, but also continuously improve skin symptoms and improve patients' quality of life. Extended-phase studies of more than one year have shown that the drug is safe and well tolerated. With the approval and promotion in more countries in the future, nemolizumab is expected to become a mainstream biological drug for the treatment of chronic itching and atopic dermatitis, providing effective and precise treatment options for patients around the world.

Reference materials:https://www.drugs.com/